You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 18, 2024

Claims for Patent: 7,541,350

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,541,350

Title:	Formulation containing anti-inflammatory androstane derivative
Abstract:	There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) ##STR00001## or a solvate thereof.
Inventor(s):	Biggadike; Keith (Stevenage, GB), Sayani; Amyn Pyarali (Mississauga, CA), Buxton; Ian Richard (Mississauga, CA), Reed; Kenton Lewis (Mississauga, CA)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	10/918,779
Patent Claims:	1. A pharmaceutical formulation comprising an aqueous suspension of particulate unsolvated polymorph Form 1 of compound of formula (I) ##STR00008## one or more suspending agents, one or more preservatives, one or more wetting agents, and one or more isotonicity adjusting agents. 2. The pharmaceutical formulation of claim 1, wherein the compound of formula (I) is present within the formulation in an amount between 0.005% and 1% (w/w), based on the total weight of the formulation. 3. A pharmaceutical formulation according to claim 2 wherein the suspending agent is one or more of microcrystalline cellulose and carboxy methylcellulose sodium, the preservative is one or more of EDTA and benzalkonium chloride, the wetting agent is one or more of polyoxyethylene (20) sorbitan monooleate and the isotonicity adjusting agent is dextrose. 4. A method of treating rhinitis comprising the nasal application of a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) ##STR00009## or a solvate thereof, one or more suspending agents one or more preservatives one or more wetting agents, and one or more isotonicity adjusting agents. 5. A method of claim 4, wherein the compound of formula (I) is used as unsolvated polymorph Form 1. 6. A method of claim 5, wherein the compound of formula (I) is present within the formulation in an amount between 0.005% and 1% (w/w), based on the total weight of the formulation. 7. The method of claim 5, wherein the suspending agent is one or more of microcrystalline cellulose and carboxy methylcellulose sodium, the preservative is one or more of EDTA and benzalkonium chloride, the wetting agent is one or more of polyoxyethylene (20) sorbitan monooleate and the isotonicity adjusting agent is dextrose.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.